Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populations
Aging in RRMS is associated with a lower risk of inflammatory disease activity, across different disease durations. Age should be taken into account when designing clinical trials and future research should investigate how age should be integrated into personalized predictions of treatment response and risk profiling.
Authors
- Jop Mostert (ORCID: https://orcid.org/0000-0003-3640-9935)
- Bernard M.J. Uitdehaag (ORCID: https://orcid.org/0000-0002-9226-7364)
- E.M.E. Coerver (ORCID: https://orcid.org/0000-0001-5673-9996)
- Zoé L. E. van Kempen (ORCID: https://orcid.org/0000-0001-9557-5381)
- Arman Eshaghi (ORCID: https://orcid.org/0000-0002-6652-3512)
- Maria Pia Sormani (ORCID: https://orcid.org/0000-0001-6892-104X)
- Frederik Barkhof (ORCID: https://orcid.org/0000-0003-3543-3706)
- Douglas Lorne Arnold (ORCID: https://orcid.org/0000-0003-4266-0106)
- Olga Ciccarelli (ORCID: https://orcid.org/0000-0001-7485-1367)
- Menno Michiel Schoonheim (ORCID: https://orcid.org/0000-0002-2504-6959)
- Joep Killestein (ORCID: https://orcid.org/0000-0002-6347-5957)
- Sezgi Kaçar (ORCID: https://orcid.org/0000-0002-6695-2667)
- Eva M.M Strijbis
- Marcus W Koch
Institutions
- Montreal Neurological Institute and Hospital (CA)
- Queen Mary University of London (GB)
- University of Calgary (CA)
- National Institute for Health and Care Research (GB)
- Amsterdam Neuroscience (NL)
- NeuroRx Research (Canada) (CA)
- Ospedale Policlinico San Martino (IT)
- National Hospital for Neurology and Neurosurgery (GB)
- Amsterdam University Medical Centers (NL)
- Rijnstate Hospital (NL)
- University College London (GB)
- McGill University (CA)
- Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Multiple Sclerosis Journal
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1177/13524585241272938
- Citations
- 9
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 3.82
Funders
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Celgene
- Atara Biotherapeutics
- International Progressive MS Alliance
- National Institute for Health and Care Research
- MedDay Pharmaceuticals
- EMD Serono
- Sanofi Genzyme
- Medical Research Council